Evidence map›Paper›PMID 38737534›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Synthesis and toxicity assessment of

Isaí Trejo-Teniente, Blanca Estela Jaramillo-Loranca, Genaro Vargas-Hernández, Maricela Villanueva-Ibáñez, Xochitl Tovar-Jiménez, Patricia Nayeli Olvera-Venegas, José Tapia-Ramírez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isaí Trejo-Teniente *Laboratory of Nanotechnology, New Materials and Systems for Health, Industry and Alternative Energies, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
Blanca Estela Jaramillo-Loranca *Laboratory of Nanotechnology, New Materials and Systems for Health, Industry and Alternative Energies, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
Genaro Vargas-HernándezLaboratory of Bioactive Compounds, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
Maricela Villanueva-IbáñezLaboratory of Nanotechnology, New Materials and Systems for Health, Industry and Alternative Energies, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
Xochitl Tovar-JiménezLaboratory of Bioactive Compounds, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
Patricia Nayeli Olvera-VenegasBiotechnology Engineering Education Program, Universidad Politécnica de Pachuca, Zempoala, Hidalgo, Mexico.
José Tapia-RamírezDepartment of Genetics and Molecular Biology, Centro de Investigaciones y de Estudios Avanzados IPN, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is the second leading cause of death worldwide, despite the many treatments available, cancer patients face side effects that reduce their quality of life. Therefore, there is a need to develop novel strategies to increase the efficacy of treatments. In this study, gold nanoparticles obtained by green synthesis with

Indexed as

biosynthesiscancerCoffea arabica extractdoxorubicingold nanoparticlesligandsnanohybrids

Identifiers

PMID38737534
PMCPMC11082400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.